Factors related with prostaglandin associated periorbitopathy (PAP) in glaucoma patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20141011001

Enrollment

150

Registered

2014-10-11

Start date

2014-06-19

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostaglandin associated periorbitopathy glaucoma ocular hypertension prostaglandin associated periorbitopathy glaucoma ocular hypertension risk factors protective factors

Interventions

Glaucoma or ocular hypertension patients who use Prostaglandin eyedrops

Treatment

prostaglandin eyedrops users

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Glaucoma or ocular hypertension patients Use prostaglandin analogs for controlling IOP Continue using for at least 3 months

Exclusion criteria

Exclusion criteria: Patients who have history of intraocular or extraocular surgery except cataract, filtering surgery, and laser treatment Patients who use other glaucoma drugs other than PGAs except timolol within 6 months Patients who have generalized lipodystrophy

Design outcomes

Primary

Measure	Time frame
Risk factors and protective factors none Photographs	—

Secondary

Measure	Time frame
Prevalence none none	—

Countries

Thailand

Contacts

Public ContactChanikarn Patradul

Faculty of Medicine, Chulalongkorn University

c.patradul@gmail.com0818678167

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026